Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EYE103
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : $3,000.0 million
Deal Type : Acquisition
Merck Completes Acquisition of EyeBio
Details : The acquisition includes Restoret (EYE103), a first-in-class tetravalent, tri-specific antibody and late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration.
Product Name : Restoret
Product Type : Other Large Molecule
Upfront Cash : $1,300.0 million
December 07, 2024
Lead Product(s) : EYE103
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : $3,000.0 million
Deal Type : Acquisition
Lead Product(s) : EYE103
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : $3,000.0 million
Deal Type : Acquisition
Details : The acquisition includes Restoret (EYE103), a first-in-class tetravalent, tri-specific antibody and late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration.
Product Name : Restoret
Product Type : Other Large Molecule
Upfront Cash : $1,300.0 million
May 29, 2024
Lead Product(s) : EYE103
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : $3,000.0 million
Deal Type : Acquisition
Lead Product(s) : EYE103
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Bain Capital Life Sciences
Deal Size : $130.0 million
Deal Type : Series A Financing
Details : The proceeds will accelerate the Company’s clinical development program and further build out its innovative retina pipeline, including intravitreal (IVT) Restoret, EYE103 in patients with diabetic macular edema and neovascular age-related macular dege...
Product Name : Restoret
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
November 14, 2023
Lead Product(s) : EYE103
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Bain Capital Life Sciences
Deal Size : $130.0 million
Deal Type : Series A Financing
Lead Product(s) : EYE103
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Restoret (EYE103) is a tri-specific Wnt agonist antibody, built based on AntlerA’s ANT-Pharm technology. It is designed to address urgent unmet medical need in patients with back-of-the-eye diseases.
Product Name : Restoret
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 14, 2023
Lead Product(s) : EYE103
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable